Las Dos Californias Inc, a San Diego food importer, lacked required foreign supplier verification programs for imported candy, seeds and Chamoy.
What happened
FDA conducted a Foreign Supplier Verification Program (FSVP) inspection of the company from October 19 through October 27, 2021, after earlier inspections on May 9, 2019 and January 17, 2018. FDA found no FSVP for foods including tamarind flavor candy and toasted pumpkin seeds, no documented review of hazard analyses, no documented supplier approval, and no written procedures. The company responded November 15, 2021 that it had hired help to develop FSVPs and estimated 8 weeks, then said December 21, 2021 that they were not ready; FDA received no additional FSVP documents.
What FDA found
Did not develop, maintain and follow a foreign supplier verification program (FSVP) for imported foods including tamarind flavor candy and toasted pumpkin seeds.
section 805 of the FD&C Act; 21 CFR 1.502(a)Did not document its review and assessment of the foreign supplier's hazard analysis or that the hazard analysis was done by a qualified individual.
21 CFR 1.504(a), (d)Did not document evaluation of a foreign supplier's performance and food risk or document approval of that supplier.
21 CFR 1.505(a)(2), (b)Did not establish written procedures for approving foreign suppliers based on performance and risk.
21 CFR 1.506(a)(1)Did not establish written procedures for ensuring appropriate foreign supplier verification activities for the Chamoy product.
21 CFR 1.506(b)
What FDA wants
Respond in writing within fifteen working days of receiving the letter, describing specific corrections and including documentation such as a copy of the FSVP and records showing implementation. If corrections cannot be completed in that time, explain the delay and state when remaining violations will be corrected.
Who should pay attention
- food importers relying on foreign suppliers
- retailers and brands selling imported Mexican snacks
- foreign suppliers shipping food to U.S. importers
This is a summary. Read the original letter on fda.gov.